Description

Brexpiprazole S-oxide-d8 is a deuterium labeled Brexpiprazole S-oxide. Brexpiprazole S-oxide is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT1A and dopamine receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM[1][2][3].–20°C, 3 years; 4°C, 2 years (Powder)-Applications-Neuroscience-Neuromodulation-Formula-C25H19D8N3O3S-Citation–References-[1]Chen B, et al. Effects of 26 Recombinant CYP3A4 Variants on Brexpiprazole Metabolism. Chem Res Toxicol. 2019 Oct 17.|[2]Ishima T, et al. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Eur Neuropsychopharmacol. 2015 Apr;25(4):505-11.|[3]Yoshimi N, et al. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol. 2015 Mar;25(3):356-64.-CASNumber-2748605-29-8-MolecularWeight-457.61-Compound Purity-98.72-SMILES-O=S1C=CC2=C(N3C([2H])([2H])C([2H])([2H])N(CCCCOC4=CC=C(C=CC(N5)=O)C5=C4)C([2H])([2H])C3([2H])[2H])C=CC=C21-Research_Area-Neurological Disease-Solubility-10 mM in DMSO-Target-5-HT Receptor;Dopamine Receptor;Isotope-Labeled Compounds-Isoform-5-HT1 Receptor;5-HT2 Receptor;D2 Receptor-Pathway-GPCR/G Protein;Neuronal Signaling;Others-MCE Product type-Isotope-Labeled Compounds